Target family: Lanosterol biosynthesis pathway (type: enzyme)
Target: lanosterol synthase

Ligand: 29-methylidene-2,3-oxidosqualene (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.52 pIC50
Reference (Journal): Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase.
Published in: J Med Chem

Ligand: compound 10 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.54 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 1 [Gotteland et al., 1997] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.15 pIC50
Reference (Journal): Design and synthesis of new potential photoaffinity labels for mammalian squalene epoxidase.
Published in: Bioorg Med Chem Lett

Ligand: compound 1 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 3 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.75 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 3 [PMID: 9003518] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase.
Published in: J Med Chem

Ligand: compound 4a [Marquart et al., 1994] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.37 pIC50
Reference (Journal): Inhibition of oxidosqualene cyclase by substituted quinolizidines.
Published in: Bioorg Med Chem Lett

Ligand: compound 4b [Marquart et al., 1994] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.77 pIC50
Reference (Journal): Inhibition of oxidosqualene cyclase by substituted quinolizidines.
Published in: Bioorg Med Chem Lett

Ligand: compound 4 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.54 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 4 [PMID: 9003518] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.59 pIC50
Reference (Journal): Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase.
Published in: J Med Chem

Ligand: compound 5 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 6 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.11 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 7 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.9 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 8 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.3 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: compound 9 [PMID: 22533316] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.95 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem

Ligand: Ro 48-8071 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.24 pIC50
Reference (Journal): Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Published in: J Med Chem